The Nodal Marginal Zone B-Cell Lymphoma drugs in development market research report provides comprehensive information on the therapeutics under development for Nodal Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Nodal Marginal Zone B-Cell Lymphoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Nodal Marginal Zone B-Cell Lymphoma and features dormant and discontinued products.
GlobalData tracks 36 drugs in development for Nodal Marginal Zone B-Cell Lymphoma by 30 companies/universities/institutes. The top development phase for Nodal Marginal Zone B-Cell Lymphoma is phase ii with 19 drugs in that stage. The Nodal Marginal Zone B-Cell Lymphoma pipeline has 28 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Nodal Marginal Zone B-Cell Lymphoma pipeline products market are: General Hospital of the People’s Liberation Army, BeiGene and Incyte.
The key targets in the Nodal Marginal Zone B-Cell Lymphoma pipeline products market include B Lymphocyte Antigen CD19, B Lymphocyte Antigen CD20, and Tyrosine Protein Kinase BTK.
The key mechanisms of action in the Nodal Marginal Zone B-Cell Lymphoma pipeline product include Tyrosine Protein Kinase BTK Inhibitor with six drugs in Phase III. The Nodal Marginal Zone B-Cell Lymphoma pipeline products include seven routes of administration with the top ROA being Intravenous and five key molecule types in the Nodal Marginal Zone B-Cell Lymphoma pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.
Nodal Marginal Zone B-Cell Lymphoma overview
Nodal marginal zone B-cell lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma that affects the lymph nodes. It is a slow-growing cancer that can sometimes become aggressive. NMZL is more common in older adults, but it can occur in younger people as well. The exact cause of NMZL is unknown, but some genetic factors may be involved. NMZL may be associated with Sjogren syndrome, an autoimmune disorder that affects the salivary and tear glands. NMZL can cause symptoms such as painless swelling of the lymph nodes, fever, night sweats, weight loss, and skin rash. The diagnosis of NMZL is based on a biopsy of the affected lymph node and other tests to determine the stage and subtype of the disease. The treatment of NMZL depends on the stage, symptoms, and general health of the patient. It may include chemotherapy, radiation therapy, surgery, or targeted therapy with monoclonal antibodies.
For a complete picture of Nodal Marginal Zone B-Cell Lymphoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
